If you have type 2 diabetes, normal liver enzyme results do not rule out metabolic dysfunction-associated steatotic liver disease (MASLD) or liver scarring. A FIB 4 score (usually written FIB-4) helps estimate the risk of advanced fibrosis using routine blood-test results and your age. If the score does not settle the question, a clinician may consider liver stiffness imaging, such as transient elastography.
That stepwise approach matters because MASLD can progress from fat buildup to inflammation and fibrosis, while liver enzymes may not show how much scarring is present. Screening is about assessing risk—not diagnosing liver disease from one number.
Why Normal Liver Enzymes Don’t Rule Out MASLD
ALT and AST are enzymes measured in blood. They can be part of a liver assessment, but they are not direct measurements of fibrosis. A normal result is reassuring in some ways, but it cannot by itself exclude MASLD or advanced scarring.
The 2024 joint guideline from the European Association for the Study of the Liver, the European Association for the Study of Diabetes and the European Association for the Study of Obesity recommends considering fibrosis case-finding in people with cardiometabolic risk factors—particularly type 2 diabetes—even when the reason for assessment is not an abnormal enzyme result. The guideline supports a sequence: start with a blood-based score such as FIB-4, then use imaging if needed.
How the FIB 4 Score Is Used
FIB-4 combines age, AST, ALT and platelet count. It is a risk-stratification tool, not a direct scan of the liver and not a diagnosis. A clinician can calculate it from blood tests already taken, or use a calculator; the inputs and units need to be entered correctly.
In commonly used pathways, a score below 1.3 is often used to indicate lower risk in adults younger than 65. For people aged 65 or older, a higher threshold—2.0—is commonly used because age itself raises FIB-4. The same result therefore may mean something different at different ages. These cutoffs guide what to consider next; they do not guarantee that fibrosis is absent or present.
For people with diabetes, a low score may not be the whole story. A 2026 study by Abdel-Aziz Shaheen and colleagues examined primary-care pathway data from Calgary and Edmonton, Canada. It compared FIB-4 with liver stiffness measured by two types of elastography in 8,126 people in Calgary and 985 in Edmonton. At the same FIB-4 level, participants with diabetes or obesity were more likely to have liver stiffness of at least 8 kPa than those without those risk factors. The researchers concluded that FIB-4 alone may under-triage people with diabetes or obesity, and said the finding needs validation in other groups. It is a reason for clinicians to consider the whole risk picture, not proof that every person with diabetes needs immediate imaging.
When Elastography May Be the Next Step
If FIB-4 is elevated, unclear, or doesn’t fit your broader risk profile, a clinician may recommend another assessment. Transient elastography—often called FibroScan, though that is a brand name—uses ultrasound-based measurements to estimate liver stiffness. Other elastography methods are also used. These tests provide additional information about fibrosis risk; they do not make every uncertainty disappear.
Depending on the result and local pathway, follow-up may involve further testing or review by a liver specialist. Ask what your result means in your case and what would trigger the next step. A calculator result on its own should not determine whether you need referral or imaging.
Age and Location Can Change the Follow-Up Plan
Age affects how FIB-4 is interpreted, while local guidelines and access to testing can shape what happens next. The European joint guideline recommends a stepwise blood-test-then-imaging approach. A 2025 clinical commentary reports that European and American liver-society pathways are broadly similar, but services and referral processes vary. There is not one follow-up schedule that applies everywhere.
If you live in the United States, United Kingdom, European Union or Australia, your clinician may follow national or local pathways that reflect available tests and services. Ask when your risk should be reassessed, especially if your first result was low but you have ongoing metabolic risk factors. Discussing your results with your diabetes or primary-care team is a useful starting point; they can decide whether another test or specialist input is appropriate. This information cannot replace an individual clinical assessment.
